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Objectives: Research networks in adult and neonatal critical care have demonstrated collaborative and successful execution of clinical trials. Such networks appear to have been relatively recently established in the field of pediatric critical care. The objective of this study was to evaluate the productivity and impact of randomized controlled trials conducted by pediatric critical care research networks, compared with nonnetwork trials. Data Sources, Study Selection, and Data Abstraction: We searched multiple online databases including MEDLINE, reference lists of randomized controlled trials, and relevant systematic reviews. Independent pairs of reviewers identified published randomized controlled trials administering any intervention to children in a PICU and abstracted data. A research network was defined as a formal consortium or collaborative research group established for the purpose of conducting clinical research. Data were independently abstracted in duplicate. Main Results: There were 288 pediatric critical care randomized controlled trials published in English between 1986 and July 2015, of which 15 randomized controlled trials (5.2%) were conducted by a total of five research networks. Network randomized controlled trials were more often multicentered, multinational, and larger in size (p < 0.001), compared with nonnetwork randomized controlled trials. Accordingly, their trials took longer to complete (median, 36 vs 21 mo; p < 0.001). Early stopping occurred in 46.7% of network randomized controlled trials (46.7%) and 27% of nonnetwork randomized controlled trials (p = 0.14), most commonly for futility. None of the network, but 45% of the nonnetwork trials found a significant difference in their primary outcome (p < 0.001). Network trials were more frequently cited (median, 6 vs 2 citations per year) and published in higher impact journals (median impact factor, 21.8 vs 3; p < 0.001). Conclusions: Research networks have conducted a minority of randomized controlled trials in pediatric critical care. They infrequently demonstrate significant differences in their primary outcomes. Despite this, network trials are cited more frequently and appear to have greater impact. There are important lessons to learn from both individual researchers as well as research networks that may guide the successful conduct of collaborative, high-quality randomized controlled trials in critically ill children. (Pediatr Crit Care Med 2016; XX:00-00) Key Words: critical care; pediatrics; randomized controlled trials; research networks C onducting randomized controlled trials (RCTs) in critically ill children is challenging given the heterogeneous patient population, complexity of consent and assent, funding limitations, and lower frequency of severe outcomes such as mortality (1) . The ethical, logistic, and methodologic challenges encountered by pediatric critical care (PCC) researchers may impact not only the quantity, but the quality of RCTs (2). Commitments to optimize the conduct of research, build capacity by sharing expertise and resources, and inform practice have led to the emergence of research groups or networks (3, 4) . Research networks have facilitated a systematic collaborative approach to successful conduct of clinical trials, advancing knowledge and improving patient outcomes in fields, such as oncology (5), stroke, diabetes (6) , and HIV/ AIDS (7) .
Critical care research consortia such as the Canadian Critical Care Trials Group (CCCTG), the Australia and New Zealand Intensive Care Society Clinical Trials Group (ANZICS-CTG), the Acute Respiratory Distress Syndrome network, and others have demonstrated how such networks can be highly productive and successful in promoting global, investigator-led, collaborative research in critically ill adults (3) . Neonatal models, such as the Vermont Oxford Network, have facilitated successful large scale, pragmatic, high-quality trials (8, 9) . Research and education in the field of PCC have progressed rapidly in the last 20 years, providing impetus for researchers to collaborate on how to address important questions, conduct well-designed RCTs, and overcome some of the methodologic and enrolment challenges in critically ill children (10) . The objective of this study was to evaluate the productivity and impact of clinical trials conducted by PCC research networks. We hypothesized that PCC research networks would be more successful in completing and publishing rigorously conducted RCTs, compared to trials conducted outside of research networks.
METHODS

Data Source
We used the evidence in pediatric intensive care database of RCTs (picutrials.net) to identify RCTs in PCC. This is a database of published RCTs in PCC, developed from a scoping review using comprehensive search strategies, of MEDLINE, EMBASE, LILACS, and CENTRAL (Updated July 7, 2015) . This database excludes crossover trials and trials enrolling only preterm infants. Further detailed methods of our search are previously published including characteristics of trials retrieved through April 2013 (11) . We defined a research network as a formal consortium, collective, cooperative, or collaborative research group established for the purpose of facilitating the conduct of clinical research. We did not consider study groups formed to conduct a single study to be research networks.
Inclusion Criteria
We included all PCC RCTs published in English. Trials were identified as being conducted by a research network if the publication reported that the project was conducted by, or in collaboration with, a research network, consortium, group or similar. RCTs not describing these criteria in their publications were considered by default to be "nonnetwork" trials. Any discrepancy or uncertainty on whether a trial was conducted by a research network was resolved by contacting the principal author of the original article. We considered a trial to be industry led if the publication reported a commercial funding source and an industry employee listed as an author, or if there was any role of the funder in the trial besides supplying of funds, supplies, or laboratory analysis. Funding was considered noncommercial if the source was from a government funding agency, university, or not-for profit organization. To reduce any effect of changes in research patterns over time, we compared the characteristics of network trials with those nonnetwork trials published from the year of the first reported network trial.
Outcomes of Interest
The outcomes of interest in this study were the productivity, efficiency, risk of bias, and impact of network and nonnetwork trials. We measured productivity by the number of trials published, their nature (i.e., pilot and full RCTs), and funding sources. We assessed efficiency by trial completion, the duration of the trial, and the number of children enrolled per center per month. We used the Cochrane risk of bias tool to assess the risk of bias (12), and we assessed impact by the 2013 impact factor of the journal and the number of times each publication was cited per year since publication using Web of Science (searched September 2015). We categorized the primary outcomes of included trials using a priori definitions, and we pretested the data abstraction tool.
Data Extraction and Analysis
Pairs of reviewers screened trials for eligibility and abstracted data independently. Discrepancies were resolved by consensus. We summarized RCT characteristics using the median (1st quartile [Q1], 3rd quartile [Q3]), and the Mann-Whitney U and Fisher exact tests to compare network with nonnetwork trial characteristics and linear regression to assess publication rates over time. We used α less than 0.05 as the criterion for statistical significance and R version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) to perform the statistical analysis.
RESULTS
There were a total of 288 PCC RCTs published in English between 1986 and July 2015, of which 15 (5.2%) were conducted by a total of five research networks ( To compare network to nonnetwork trial characteristics, we included only nonnetwork RCTs published from 1999 onwards (n = 225), the year that the first network RCT was published. Table 1 summarizes the PCC RCTs conducted by each of the five research networks we identified. We categorized these networks and the number of RCTs that they conducted as follows: 1) Investigator-initiated networks: these included the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI; seven RCTs) (13) (14) (15) (16) (17) (18) (19) , the CCCTG (three RCTs) (20) (21) (22) , and the ANZICS-CTG (one RCT) (23) , joint enterprise between the CCCTG and PALISI (one RCT) (24) , and the Pediatric Traumatic Brain Injury Consortium (one RCT) (25); and 2) Funder-initiated networks: which consisted of the National Institute of Child Health and Human Development Collaborative PCC Research Network (CPC-CRN; two RCTs) (26, 27) .
The characteristics of network and nonnetwork trials are presented in Table 2 . All RCTs (100%) conducted by research networks were multicentered and 60.0% were multinational, compared to only 16.9% and 6.2% of nonnetwork trials, respectively (p < 0.001 for both comparisons). Although the largest PCC RCT to date was not conducted by a research network (28) , network trials tend to be larger (median sample size of 152 vs 50), report slower enrolment rates per site, and take longer to complete compared to nonnetwork RCTs (median, 36 vs 21 mo; p < 0.001). We identified 13 "large" PCC RCTs, in the top decile for sample size for all included trials (i.e., more than 220 children randomized). Large PCC RCTs comprised five of 15 (33.3%) of the network trials and eight of 225 (3.6%) of the nonnetwork trials. All of the 15 network trials (100.0%) reported their sources of funding, compared to 129 nonnetwork trials (57.3%) (p < 0.001). The commonest source of funding in both groups was noncommercial. Twelve nonnetwork trials (9.3%) reported that they conducted the trial without any external funding. The proportion of network and nonnetwork trials that were at high risk of bias was not significantly different. RCTs published by PCC research networks have been cited more frequently by other authors (Fig. 3) , and are more likely to be published in higher impact journals; the median impact factor of 21.8 (4.9, 30.4) for network trials versus 3.0 (2.2, 5.5) for nonnetwork trials (p < 0.001).
The primary outcome of interest was reported explicitly by 240 of the 288 RCTs ( Table 3) . The most common primary outcomes in network trials were duration of mechanical ventilation and mortality, while in nonnetwork trials, the primary outcomes were most commonly not reported, or were shortterm clinical or physiologic outcomes. We assessed the primary outcome results of the 13 network and 150 nonnetwork trials that reported a two-arm superiority design: 68 (45.3%) of the 150 nonnetwork trials reported a statistically significant difference between the treatment groups for their primary outcome, 67 (98.5%) of which were positive (i.e., found the experimental treatment arm to be superior). In contrast, none of the 13 network two-arm superiority trials demonstrated a statistical significant difference in their primary outcome (p < 0.001). Early stopping was frequent (46.7% of network RCTs vs 27.0% of nonnetwork RCTs; p = 0.14), most commonly for futility (Table 2) .
DISCUSSION
Well-conducted RCTs have been widely accepted as the highest level of evidence informing clinical care for most preventive and therapeutic interventions. Collaborative research networks may be a fruitful means of overcoming some of the barriers to conducting rigorously designed RCTs with clinically important outcomes in critically ill children. We were able to identify only five research networks in PCC, originating in North America (PALISI, CCCTG, and CPCCRN), Australia and New Zealand (ANZICS-CTG), with one of these continents plus members However, compared to nonnetwork RCTs, network trials have been larger in sample size, targeted more clinically important outcomes, were more likely to be funded, and were more frequently published in higher impact journals and then cited. While we hypothesized that research networks would be more efficient in conducting RCTs, we found that network trials had slower enrolment rates and took longer to complete than nonnetwork RCTs. As all network trials were multicentered and half were multinational; this may reflect the selected PCC population studied and the network approaches to conducting multicentered trials, where a slower than expected recruitment rate is commonly observed (29) .
A remarkable proportion of network (47%) and nonnetwork (27%) trials were stopped early, most commonly for futility. The reasons that this appears more frequently among network trials may be explained by their selection of clinically important primary outcomes, estimates of effect size, larger sample size requirements, inherent design elements, such as prespecified stopping rules, greater costs, and transparent reporting. The decision to terminate a trial early is complex and difficult (30) . Effects may be overestimated when trials are stopped early for benefit, and some recommend against early stopping for this reason (31) . Stopping early where there is no benefit is often rationalized by the opportunity cost, the financial burden of continuing, and preventing exposure of patients to an ineffective treatment. However, stopping early for futility also has its potential disadvantages; it increases the risk of imbalance in prognostic factors, widens CIs around the primary outcome and jeopardizes the interpretation of secondary outcomes (32) .
It is interesting that none of the network superiority trials found a significant difference in their primary outcomes, while approximately half the nonnetwork trials were positive in favor of the intervention arm. This may reflect the fact that nonnetwork trials tend to be smaller, employ physiologic or surrogate outcomes, and are more likely single centered. This observation is not unique to PCC. Single center trials are often accused of an inflated effect size, particularly when subsequent larger multicenter, larger trials fail to duplicate their results (33, 34) . Network trials appear to avoid surrogate primary outcomes, which can be more responsive to trial interventions than clinically important outcomes-a phenomenon that underscores the importance of moving beyond surrogate endpoints when selecting primary outcomes for PCC RCTs. It is important to emphasize that wellconducted, adequately powered PCC RCTs that are labeled as "negative" because they failed to demonstrate a significant difference, are immensely important because they inform us of interventions that are not effective, and inform clinical practice with evidence. This explains why negative and noninferiority network trials have succeeded in being published in high impact journals. This work illustrates the challenges of designing and conducting clinical trials in critically ill children. Overall, PCC RCTs are generally small, single centered, are challenging to recruit into and complete, and most commonly measure short-term or surrogate end-points (11) . In contrast to many adult ICUs, PCC units are fewer in number, have significantly lower admission and mortality rates, a heterogeneous case mix, and smaller eligible pools of patients. Therefore, it is not unusual in a PCC RCT to require more than a dozen participating centers in several countries over 2 years to recruit a modest sample size of 100 critically ill children. It is important to note that only five of 15 trials conducted by networks focused on interventions specific to children. These included four trials of endotracheal surfactant for severe lung disease with acute respiratory failure in children and one trial of Heliox for critically ill young children with bronchiolitis. The other trials (10/15) were designed to replicate findings from adult studies in pediatric cohorts. These included four trials of hypothermia versus normothermia with three in traumatic brain injury. As there is heterogeneity in treatment effects of interventions between adults and children (35) , it was important to conduct definitive trials of these promising therapies specifically in the pediatric population, to inform clinical practice in children.
Our study has limitations. We may have omitted other networks because we included only RCTs published in English and we relied on explicit reporting by authors in the publications to identify research networks. We based our assessment of the impact of each RCT on citation rates and journal impact factor; we did not evaluate the influence of such publications on knowledge translation activities, such as evidence-based guidelines or changes in clinical practice. Finally, we did not include observational study designs, acknowledging that there are many such studies that have influenced PCC practice and research agendas (36, 37) .
Conducting high-quality PCC research is essential but difficult. Robust evidence for many interventions in critically ill children is still lacking. Not all RCTs conducted in adults need to be replicated in children, yet some are essential, particularly where the intervention under consideration may be the same (e.g., sedation), but the selected outcomes in children have unique considerations, such as functional recovery and neurodevelopment. In the era of limited resources (patients, personnel, and funding), research networks may be a mechanism for promoting and prioritizing research direction and goals for critically ill children.
There are important lessons to learn from individual researchers as well as research networks that may guide us in conducting rigorously designed, high-quality, pragmatic, and efficiently conducted RCTs to inform the care of critically ill children. As the first PCC research network project was published relatively recently (19) , it is important to continue evaluating the contribution of such networks. Research networks help to identify and prioritize research agendas, establish themes of common interest, and promote investigator-led PCC research. They can provide a platform for increased research capacity, international collaboration and may encourage synergies between pediatric and adult thematic programs, or translational, clinical, and health services research (3). Networking fosters collaboration across boundaries, to assemble and address important research questions in critically ill children. The careers of junior investigators may be particularly enhanced through network membership and mentorship. Sharing information among networks may help clinicians, scientists, and other stakeholders understand more about research infrastructure and operations, thereby supporting all members while building and sustaining a culture of collaboration.
CONCLUSION
Research networks have conducted a minority of RCTs in PCC, however, a much higher percentage of their trials are large compared to nonnetwork trials. PCC research networks have focused over half of their trials to date on two interventions: hypothermia versus normothermia and endotracheal surfactant versus control. Although network trials infrequently demonstrate significant differences in their primary outcomes and are commonly stopped early, many were designed to replicate studies of interventions that appeared promising in adult populations or in small single center pediatric studies to determine potential risk/benefit for children. Network trials appear to have greater impact in terms of citations and journal publication, but their influence on clinical care must be assessed. 
